In-depth profile of Esperion Therapeuticsin Ann Arbor's tech ecosystem
Esperion Therapeutics is the Ann Arbor biotech company that has become a serious player in the cardiovascular drug market. Founded in its current form in 2008 by Roger Newton, who previously co-invented Lipitor at Pfizer, Esperion develops small-molecule therapies that target LDL cholesterol for patients who cannot tolerate statins. The company's flagship drugs Nexletol and Nexlizet have been approved by the FDA and are now being prescribed across cardiology and primary care.
The scientific program is serious medicine. Esperion's lead compound, bempedoic acid, works on an upstream enzyme in the cholesterol synthesis pathway and meaningfully reduces LDL in patients where statins fail or cause side effects. The company completed the CLEAR Outcomes trial in 2023, which demonstrated significant cardiovascular event reduction, and the drug is now incorporated into national guidelines. For a locally-headquartered biotech, that is a substantial clinical and commercial achievement.
Esperion's Ann Arbor presence reflects the depth of the local life sciences ecosystem. Michigan Medicine is a top academic medical center, and the U-M College of Pharmacy, School of Public Health, and Life Sciences Institute produce the scientific talent that Esperion and its peers need. The company operates out of a Domino's Farms office complex, which sits in a distinctive frank-lloyd-wright-inspired campus on the east side of town.
For biotech and pharma professionals, whether in clinical development, regulatory affairs, commercial, or data science roles, Esperion represents the kind of mid-sized, publicly traded, mission-driven biotech that tech hubs like Cambridge and the Bay Area have but that most of the Midwest does not. The Ann Arbor lifestyle package applies fully, and the company's work directly contributes to reducing cardiovascular disease, which is still the leading cause of death in the United States.